Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
While Sanofi's antacid medicine Zantac (ranitidine) and its generic versions face immediate withdrawal in the US due to nitrosamine impurities, the European Medicines Agency is continuing to conduct its own review of ranitidine-containing medicines and “will formulate an opinion in due course.”
The next discussion on the safety of ranitidine medicines is foreseen later this month when the EMA’s human medicines evaluation...
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
